Literature DB >> 14616364

Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin.

I C Le Poole1, L S Stennett, B K Bonish, L Dee, J K Robinson, C Hernandez, S K Hann, B J Nickoloff.   

Abstract

BACKGROUND: Detection of CDw60 in skin is representative of ganglioside D3 expression. This ganglioside is expressed primarily by melanocytes, and is of interest as a membrane antigen targeted by immunotherapy for melanoma patients. Expression of CDw60 by keratinocytes is defined by the presence of T-helper cell (Th)1 vs. Th2 cytokines, and can serve as a sentinel molecule to characterize an ongoing skin immune response.
OBJECTIVES: These immunobiological characteristics have provided the incentive to study the expression of CDw60 in the context of progressive vitiligo.
METHODS: Frozen sections were obtained from control skin and from vitiligo lesions and immunostained to show CDw60. Cells were cultured, their CDw60 expression studied and ribonuclease protection assays run to detect cytokine mRNA.
RESULTS: Resistance to cytokine-mediated regulation of CDw60 expression was demonstrated in vitro by melanocytes, which appeared capable of generating autocrine and paracrine regulatory molecules supporting CDw60 expression. Induction of CDw60 expression was inhibited by antibodies to interleukin (IL)-4, suggesting that this cytokine was responsible, at least in part, for melanocyte-induced CDw60 expression. Marginal skin from patients with progressive generalized vitiligo consistently showed a reduction in epidermal CDw60 expression alongside elevated human leucocyte associated antigen (HLA)-DR expression at the margin. It thus appears that inflammatory infiltrates present in marginal skin generate type 1 rather than type 2 cytokines, supportive of a cell-mediated autoimmune response.
CONCLUSIONS: These results support an active role of melanocytes within the skin immune system, and associate their loss in generalized vitiligo with a cell-mediated immune response mediated by type 1 cytokines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616364     DOI: 10.1046/j.1365-2133.2003.05539.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo.

Authors:  Tara M Kroll; Hemamalini Bommiasamy; Raymond E Boissy; Claudia Hernandez; Brian J Nickoloff; Ruben Mestril; I Caroline Le Poole
Journal:  J Invest Dermatol       Date:  2005-04       Impact factor: 8.551

Review 2.  The convergence theory for vitiligo: A reappraisal.

Authors:  Roopal V Kundu; Julia M Mhlaba; Stephanie M Rangel; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2018-06-28       Impact factor: 3.960

Review 3.  Therapeutic implications of autoimmune vitiligo T cells.

Authors:  Kepa Oyarbide-Valencia; Jasper G van den Boorn; Cecele J Denman; Mingli Li; Jeremy M Carlson; Claudia Hernandez; Michael I Nishimura; Pranab K Das; Rosalie M Luiten; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2006-05-06       Impact factor: 9.754

4.  Vitiligo: a review of some facts lesser known about depigmentation.

Authors:  James J Nordlund
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

Review 5.  Engineered antigen-specific regulatory T cells for autoimmune skin conditions.

Authors:  Zhussipbek Mukhatayev; Yekaterina O Ostapchuk; Deyu Fang; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2021-01-18       Impact factor: 17.390

Review 6.  Vitiligo--part 1.

Authors:  Roberto Gomes Tarlé; Liliane Machado do Nascimento; Marcelo Távora Mira; Caio Cesar Silva de Castro
Journal:  An Bras Dermatol       Date:  2014 May-Jun       Impact factor: 1.896

7.  Therapeutic effects of iNOS inhibition against vitiligo in an animal model.

Authors:  Hamid Mansourpour; Katayoun Ziari; Sahar Kalantar Motamedi; Amin Hassan Poor
Journal:  Eur J Transl Myol       Date:  2019-08-06

8.  Antigen Specificity Enhances Disease Control by Tregs in Vitiligo.

Authors:  Zhussipbek Mukhatayev; Emilia R Dellacecca; Cormac Cosgrove; Rohan Shivde; Dinesh Jaishankar; Katherine Pontarolo-Maag; Jonathan M Eby; Steven W Henning; Yekaterina O Ostapchuk; Kettil Cedercreutz; Alpamys Issanov; Shikhar Mehrotra; Andreas Overbeck; Richard P Junghans; Joseph R Leventhal; I Caroline Le Poole
Journal:  Front Immunol       Date:  2020-12-01       Impact factor: 7.561

9.  Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice.

Authors:  Ancy Thomas; Saurav Sumughan; Emilia R Dellacecca; Rohan S Shivde; Nicola Lancki; Zhussipbek Mukhatayev; Cristina C Vaca; Fei Han; Levi Barse; Steven W Henning; Jesus Zamora-Pineda; Suhail Akhtar; Nikhilesh Gupta; Jasmine O Zahid; Stephanie R Zack; Prathyaya Ramesh; Dinesh Jaishankar; Agnes Sy Lo; Joel Moss; Maria M Picken; Thomas N Darling; Denise M Scholtens; Daniel F Dilling; Richard P Junghans; I Caroline Le Poole
Journal:  JCI Insight       Date:  2021-11-22

10.  Clinical patterns of vitiligo and its associated co morbidities: A prospective controlled cross-sectional study in South India.

Authors:  D S Krupa Shankar; K Shashikala; Rama Madala
Journal:  Indian Dermatol Online J       Date:  2012-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.